Comments on the ACD Received from the Public through the NICE Website

Name	[redacted]
Role	NHS Professional- Consultant in Haematology
Location	England
Conflict	
Date	5 October 2014
Comment 1	
Page (from)	
Page (to)	
Line number(s)	
Section (from)	
Section (to)	
Comment	I would like to support the proposal for use of obinutuzumab in this indication. A very significant achievement with the study was the achievement of negative minimal residual disease in over 30% of patients who received obinutuzumab. This is not seen with many others therapies for CLL - and was not detectable at all with the rituximab arm. Experience in many trials of drugs in CLL has shown that the 'depth' of the response to treatment is highly predictive of subsequent overall time to next treatment and to overall survival. It is therefore highly likely that the positive results for this new antibody on negative MRD will translate directly into an improvement in overall survival.